This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccines, Biologics &
​​​​​​​Small-molecule MedicinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

AboutAboutAbout ATTR-CMMOD/MOAStudy DesignDosingEfficacy & SafetyAccess & SupportAccess & SupportAccess & Patient SupportEventsMaterialsVideos
Prescribing InformationPatient InformationIndication Patient Site
Access & Patient Support

Patient access and reimbursement

Financial assistance options

Additional support during treatment

Tab Number 4

Tab Number 5

When you've decided VYNDAMAX® (tafamidis) is appropriate for your patient, VyndaLink can help*Enroll your patients in VyndaLink for support

The VyndaLink team can:

 Conduct a benefits verification to determine your patient's coverage for VYNDAMAX, including out-of-pocket costs Determine payer requirements and provide information about the prior authorization process and appeals process as needed† Identify Specialty Pharmacy options based on your patient’s insurance coverage. VYNDAMAX is available through multiple Specialty Pharmacies in our defined distribution networkThe same VyndaLink support offerings available to patients prescribed VYNDAMAX are also available to patients prescribed VYNDAQEL (tafamidis meglumine).Please note where a PA is required, the physician must submit required information directly to the patient's insurer.

Get started at www.VyndaLink.com

Download the enrollment form and fax completed forms to 1-888-878-8474. You can also complete the enrollment form online at www.VyndaLinkPortal.com. Call VyndaLink at 1-888-222-8475 (Monday-Friday, 8 AM-8 PM ET) with any questions.

 Visit VyndaLink Loading Next: Financial assistance options Continue Loading
When you've decided VYNDAMAX® (tafamidis) is appropriate for your patient, VyndaLink can help*VyndaLink can help connect your patients with potential financial assistance options
  • Medicare/Government-Insured Patients:
    • For those patients who need help with their medication cost-sharing requirements, VyndaLink can refer patients who may be eligible to Medicare Extra Help or alternate sources of funding
    • If support through an alternate funding source is not available, some patients may be eligible to receive VYNDAMAX at no cost through the Pfizer Patient Assistance Program.† Patients must reapply annually
  • Commercially-Insured Patients:
    • Eligible commercially-insured patients may pay as little as $0 per month through the VYNDAMAX Co-pay Savings Program‡
  • Uninsured patients:
    • VyndaLink will check if your patient may appear eligible for Medicaid and can tell them how to contact Medicaid to apply
    • VyndaLink may be able to help your eligible uninsured patients receive VYNDAMAX while applying for Medicaid, for up to 90 days, through the Pfizer Patient Assistance Program†
    • If your patients do not qualify for Medicaid, they may be able to get up to a 1-year free supply of VYNDAMAX through the Pfizer Patient Assistance Program.† Patients must meet eligibility requirements and reapply as needed
The same VyndaLink support offerings available to patients prescribed VYNDAMAX are also available to patients prescribed VYNDAQEL (tafamidis meglumine). Criteria depend on a number of factors, including the specific medicine prescribed, insurance status, and household size and income. The Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance FoundationTM. The Pfizer Patient Assistance Program is a separate legal entity from Pfizer Inc., with distinct legal restrictions.Limits, terms, and conditions apply. Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico. Patients may receive up to $60,000 in savings annually. The offer will be accepted only at participating pharmacies. This offer is not health insurance. No membership fees apply. Pfizer reserves the right to rescind, revoke, or amend this offer without notice. For any questions, please call 1-888-222-8475 or write: Pfizer, ATTN: Claims Processing Department, IQVIA, Inc. 77 Corporate Drive, Bridgewater, NJ 08807. Click here for full terms and conditions.Co-pay assistance

Eligible commercially-insured patients may pay as little as $0 per month through the VYNDAMAX Co-pay Savings Program

 Get the card now  LoadingGet started at www.VyndaLink.com

Download the enrollment form and fax completed forms to 1-888-878-8474. You can also complete the enrollment form online at www.VyndaLinkPortal.com. Call VyndaLink at 1-888-222-8475 (Monday-Friday, 8 AM-8 PM ET) with any questions.

 Visit VyndaLink LoadingTERMS AND CONDITIONS FOR CO-PAY SAVINGS PROGRAMVYNDAMAX CO-PAY SAVINGS PROGRAM TERMS AND CONDITIONS

By using this co-pay card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

  • Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
  • Patient must have private insurance. Offer is not valid for cash-paying patients. Patients are responsible for as little as a $0 monthly co-payment based upon program utilization. The value of this co-pay card is limited to a maximum of $60,000 per calendar year.
  • This co-pay card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
  • You must deduct the value of this co-pay card from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
  • You are responsible for reporting use of the co-pay card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards.
  • You must be 18 years of age or older to redeem the co-pay card.
  • This co-pay card is not valid where prohibited by law.
  • Co-pay card cannot be combined with any other savings, free trial, or similar offer for the specified prescription.
  • Co-pay card will be accepted only at participating pharmacies.
  • This co-pay card is not health insurance.
  • Offer good only in the U.S. and Puerto Rico.
  • Co-pay card is limited to 1 per person during this offering period and is not transferable.
  • A co-pay card may be redeemed for either a VYNDAMAX or VYNDAQEL prescription, but not more than once per 24 days per patient.
  • No other purchase is necessary.
  • No membership fee.
  • Data related to your redemption of the co-pay card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you.
  • Pfizer reserves the right to rescind, revoke or amend this offer without notice.
  • Offer expires 12/31/2021.
For more information, visit our website www.VyndaLink.com,
call 1-888-222-8475, or write:
Pfizer Attn: Claims Processing Department, IQVIA, Inc. 77 Corporate Drive, Bridgewater, NJ 08807 Next: Additional support during treatment Continue Loading
When you've decided VYNDAMAX® (tafamidis) is appropriate for your patient, VyndaLink can help*

Dedicated VyndaLink Patient Support Navigators can assist your patients†

 Counseling and social support

Connect patients to support groups and online communities that can offer additional support

 Patient education

Direct patients to advocacy organizations and educational resources

 Transportation

Refer patients to independent organizations that can help eligible individuals find rides and lodging for treatment­-related appointments

 Regular check-ins

Outreach from Patient Support Navigators to patients to discuss changes in their treatment or coverage that might impact their support needs

The same VyndaLink support offerings available to patients prescribed VYNDAMAX are also available to patients prescribed VYNDAQEL (tafamidis meglumine).Patients who are interested must opt in to the Patient Support Navigator program. Some offerings are provided through third-party organizations that operate independently and are not controlled by Pfizer. Availability of patient support and eligibility requirements are determined solely by these organizations.Get started at www.VyndaLink.com

Download the enrollment form and fax completed forms to 1-888-878-8474. You can also complete the enrollment form online at www.VyndaLinkPortal.com. Call VyndaLink at 1-888-222-8475 (Monday-Friday, 8 AM-8 PM ET) with any questions.

 Visit VyndaLink Loading Next: Professional resources Continue Loading
VYNDAMAX® AND VYNDAQEL® are registered trademarks of Pfizer Inc.
VyndaLink.com has more information about support services for you and your patients View VyndaLink Loading Access resources for you and your patient Explore resources Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2022 Pfizer Inc. All rights reserved.

PP-VDM-USA-1008
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-VDM-USA-0908
INDICATION AND LIMITATIONS OF USEVYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.Please see Full Prescribing Information including Patient Information.
Important Safety Information

Adverse Reactions

In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with VYNDAQEL® (tafamidis meglumine) was similar to placebo.

Specific Populations​​​​​​​

Pregnancy: Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to a pregnant woman.

Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be present in human milk. Breastfeeding is not recommended during treatment with VYNDAQEL and VYNDAMAX.

Indication VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

Please see Full Prescribing Information including Patient Information.

Please see full Prescribing Information.

OK. We'll need you to sign in before we can determine if you are aligned with a sales representative.

If you select 'Yes', you will be required to enter your username and password in the sign-in form that will appear over this window.

Would you like to sign in now?